ETF Quote Details
|NAV (month end)||130.48|
|Premium (+)/Discount (-) (month end)||-2.57|
Zacks Premium Research for XBI
|Zacks ETF Rank [?]||Strong Buy 1|
|ETF Risk [?]||High|
Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.
This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:
Zacks Premium - The only way to get access to the Zacks Rank
ETF Expense Ratio
|Dividend (Yield)||$0.38 (0.30%)|
|Issuer||STATE STREET GLOBAL ADVISORS|
The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the U.S. common stocks listed on the NYSE, AMEX, NASDAQ National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
The SPDR S&P Biotech ETF, before expenses, seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index.